Current drug delivery
Cure8 research brief
Why This Matters
This preclinical study reports a new pH-sensitive liposomal formulation that increased intestinal delivery and anti-inflammatory effects of roxadustat in animal models of colitis, which could be relevant to future oral IBD therapies.
Who Should Pay Attention
Researchers in drug delivery and IBD, translational clinicians, and patients interested in emerging oral treatment approaches for intestinal inflammation.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study describes a formulation (ROX-MAE@LP) designed to protect roxadustat in the stomach and release it in the intestine, showing higher drug levels after oral dosing in rats and greater reduction of inflammation in a DSS mouse colitis model.
The findings are preclinical (cell and animal) and focus on formulation and delivery rather than human safety or efficacy. The research suggests pH-sensitive, intestine-targeted nanocarriers can improve local drug concentration and mucosal healing in experimental colitis, supporting further development but not yet clinical use.
Keep In Mind
Results are from cell and animal models (rats and DSS-induced colitis mice) described in the article abstract; human safety and efficacy are not addressed here.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCurrent drug delivery
AuthorsKong G, Zheng Y, Lu Y +2 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
Targeted β-Glucan-Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis-Associated Gut Microbiota and Alleviates Ulcerative Colitis-Associated Anxiety, Depression, and Neuropsychiatric Behaviors.
People with IBD often have higher rates of anxiety and depression; this study suggests an experimental oral nanotherapy carrying apremilast might treat both gut inflammation and related neuropsychiatric symptoms in...
A natural product-based pH-responsive hydrogel nanoplatform for ulcerative colitis therapy via synchronous regulation of immune microenvironment and intestinal barrier.
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...